Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
The institution of a "Cardioprophylactic" drug regimen after myocardial infarction should take into consideration the concept of high or low risk patients for secondary coronary events and the concept of a decremential mortality rate as time elapses after myocardial infarction. Thus, the efficacy of a particular drug in preventing secondary coronary events may vary with the time elapsed from infarction and thus with the underlying patho-physiologic mechanism. Furthermore, the administration of a possible effective or proven effective "Cardioprophylactic" drug or drug regimen at a specific time from infarction must take into account the balance between expected benefit and untoward side effects.
Bélanger
G L
GL
Lavallée
J P
JP
Lenis
J
J
Ouellet
C A
CA
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D004176:Dipyridamole / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications*; D013442:Sulfinpyrazone / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone